Celgene CEO affirms Growth Till 2020
Celgene one of the biggest biotechs out there.
They have a huge presence in cancer, specifically multiple myeloma (bone cancer), and they have a tremendous number of different collaborations and pipeline candidates that are going to be rolling out data over the course of 2017 and 2018 that can move this stock higher.
Total revenue soared 16.3% to $2.98 billion in the fourth quarter of 2016. Revenues were boosted by a consistently strong performance by the company’s key growth driver, Revlimid.
Excluding share-based compensation expense, Celgene’s earnings climbed approximately 36.4% year over year to $1.61 in the reported quarter.
Given the fact that they're targeting a disease that requires treatment, they've escaped some of the pushback on pricing that maybe others have endured more of, so they should be fine on that front.
There are very few biotech companies out there that have offered up guidance from 2017 to 2020. Celgene is forecasting pretty remarkable top- and bottom-line growth.
If they can hit their internal forecasts, investors will be rewarded.
CEO of Celgene had affirmed top and bottomline growth till year 2020: https://youtu.be/2fsUYGDqpQY
Celgene's past earnings and expected earnings:
They have a huge presence in cancer, specifically multiple myeloma (bone cancer), and they have a tremendous number of different collaborations and pipeline candidates that are going to be rolling out data over the course of 2017 and 2018 that can move this stock higher.
Total revenue soared 16.3% to $2.98 billion in the fourth quarter of 2016. Revenues were boosted by a consistently strong performance by the company’s key growth driver, Revlimid.
Excluding share-based compensation expense, Celgene’s earnings climbed approximately 36.4% year over year to $1.61 in the reported quarter.
Given the fact that they're targeting a disease that requires treatment, they've escaped some of the pushback on pricing that maybe others have endured more of, so they should be fine on that front.
There are very few biotech companies out there that have offered up guidance from 2017 to 2020. Celgene is forecasting pretty remarkable top- and bottom-line growth.
If they can hit their internal forecasts, investors will be rewarded.
CEO of Celgene had affirmed top and bottomline growth till year 2020: https://youtu.be/2fsUYGDqpQY
Celgene's past earnings and expected earnings:
Comments
Post a Comment